Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome

Clinical trials have demonstrated that lonafarnib, a farnesyltransferase inhibitor, extends the lifespan in patients afflicted by Hutchinson-Gilford progeria syndrome, a devastating condition that accelerates many characteristics of aging and results in premature death due to cardiovascular sequelae...

Descripción completa

Detalles Bibliográficos
Autores principales: Murtada, Sae-Il, Mikush, Nicole, Wang, Mo, Ren, Pengwei, Kawamura, Yuki, Ramachandra, Abhay B, Li, David S, Braddock, Demetrios T, Tellides, George, Gordon, Leslie B, Humphrey, Jay D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Physics of Living Systems
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023154/
https://www.ncbi.nlm.nih.gov/pubmed/36930696
http://dx.doi.org/10.7554/eLife.82728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023154/
https://www.ncbi.nlm.nih.gov/pubmed/36930696
http://dx.doi.org/10.7554/eLife.82728

Ejemplares similares